The activation of cyclin D and CDK4/6, which play pivotal roles in the transition from G1 to S phase, is a feature of many cancer cell types, particularly breast cancer cells [95, 96, 97], and so both have been targeted therapeutically. This evidence concerns the gene CDK4 and cancer.